ATE497960T1 - A1-adenosinrezeptoragonisten - Google Patents

A1-adenosinrezeptoragonisten

Info

Publication number
ATE497960T1
ATE497960T1 AT06825861T AT06825861T ATE497960T1 AT E497960 T1 ATE497960 T1 AT E497960T1 AT 06825861 T AT06825861 T AT 06825861T AT 06825861 T AT06825861 T AT 06825861T AT E497960 T1 ATE497960 T1 AT E497960T1
Authority
AT
Austria
Prior art keywords
receptor agonists
adenosine receptor
angina
release
useful
Prior art date
Application number
AT06825861T
Other languages
German (de)
English (en)
Inventor
Elfatih Elzein
Xiaofen Li
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE497960T1 publication Critical patent/ATE497960T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT06825861T 2005-10-13 2006-10-11 A1-adenosinrezeptoragonisten ATE497960T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72661605P 2005-10-13 2005-10-13
PCT/US2006/039975 WO2007047401A2 (en) 2005-10-13 2006-10-11 A1 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
ATE497960T1 true ATE497960T1 (de) 2011-02-15

Family

ID=37865975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06825861T ATE497960T1 (de) 2005-10-13 2006-10-11 A1-adenosinrezeptoragonisten

Country Status (8)

Country Link
US (2) US7488720B2 (cg-RX-API-DMAC10.html)
EP (1) EP1943251B8 (cg-RX-API-DMAC10.html)
JP (1) JP2009511593A (cg-RX-API-DMAC10.html)
AT (1) ATE497960T1 (cg-RX-API-DMAC10.html)
CA (1) CA2625783A1 (cg-RX-API-DMAC10.html)
DE (1) DE602006020057D1 (cg-RX-API-DMAC10.html)
ES (1) ES2358351T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007047401A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488720B2 (en) * 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
EP4541803A4 (en) * 2022-06-17 2025-10-01 Shanghai Senhui Medicine Co Ltd CYCLOPENTYLADENOSINE DERIVATIVE AND ITS PHARMACEUTICAL USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2264826T3 (es) * 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
WO2004069185A2 (en) * 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
US7488720B2 (en) * 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists

Also Published As

Publication number Publication date
EP1943251A2 (en) 2008-07-16
WO2007047401A3 (en) 2007-06-14
ES2358351T8 (es) 2011-06-15
JP2009511593A (ja) 2009-03-19
WO2007047401A2 (en) 2007-04-26
CA2625783A1 (en) 2007-04-26
US20090137520A1 (en) 2009-05-28
US20070087994A1 (en) 2007-04-19
DE602006020057D1 (de) 2011-03-24
US7488720B2 (en) 2009-02-10
EP1943251B8 (en) 2011-03-23
ES2358351T3 (es) 2011-05-09
EP1943251B1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
EA200800100A1 (ru) Соединения азаиндазола и способы применения
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
IN2012DN02452A (cg-RX-API-DMAC10.html)
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
NO20081211L (no) Xantinderivater som selektive HM74A agonister
AR075604A1 (es) Anticuerpos contra un ligando que induce proliferacion (april)
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
EA201071221A1 (ru) Гетероциклические соединения
WO2010006189A3 (en) Small-molecule inhibitors of hif and angiogenesis
ES2337973B8 (es) Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
EA201270204A1 (ru) Таблетка
DE602006020057D1 (de) A1-adenosinrezeptoragonisten
TW200616649A (en) Partial and full agonists of A1 adenosine receptors
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
EA200701592A1 (ru) Композиты и способы их получения и использования
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
TW200621793A (en) Partial and full agonists of a1 adenosine receptors
CL2007001091A1 (es) Compuestos derivados de ciclopropan dicarboxamida, inhibidores del factor de coagulacion xa; composiciones farmaceuticas; y su uso para tratar desordenes tromboticos, trombosis arterial o venosa, trombosis venosa profunda, enfermedad arterial periferica oclusiva y angina pectoris inestable, infarto al miocardio, entre otras.
WO2006116197A3 (en) Methods of identifying individuals at risk of perioperative myocardial injury, major adverse cardiac events, cognitive decline, arrhythmias, depression or bleeding
FR2889976B1 (fr) Appaeil de traitement par voie humide.
ECSP088994A (es) INHIBIDORES DE CANAL DE POTASIO Kv1.5
CL2007002918A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
CL2011000921A1 (es) Sal cristalina del ester del acido butirico (1r, 2r, 4r)-2-(2-{[3-(4,7-dimetoxi-1h-benzoimidazol-2-il)-propil]-metil-amino}-etil)-5-fenil-biciclo[2.2.2]oct-5-en-2-ilo; composicion farmaceutica; y su uso para el tratamiento o la prevencion de angina estable, hipertension, isquemia renal o cardiaca, entre otras.
TH83828B (th) ชิ้นส่วนรองเท้า

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1943251

Country of ref document: EP